Evidence map›Paper›PMID 34421491›Full record

ArticleEJIFCC2021

Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay.

Gian Luca Salvagno, Gianluca Gianfilippi, Giacomo Fiorio, Laura Pighi, Simone De Nitto, Brandon M Henry, Giuseppe Lippi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in EJIFCC, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Gian Luca SalvagnoSection of Clinical Biochemistry, University of Verona, Verona, Italy.
Gianluca GianfilippiMedical Direction, Pederzoli Hospital, Peschiera del Garda, Italy.
Giacomo FiorioMedical Direction, Pederzoli Hospital, Peschiera del Garda, Italy.
Laura PighiSection of Clinical Biochemistry, University of Verona, Verona, Italy.
Simone De NittoSection of Clinical Biochemistry, University of Verona, Verona, Italy.
Brandon M HenryThe Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Giuseppe LippiSection of Clinical Biochemistry, University of Verona, Verona, Italy.
University of Verona · ITCasa di Cura Villa Garda · ITCincinnati Children's Hospital Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to the large volume of tests needed in a relatively short time for screening and diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, antigen immunoassays may provide a potential supplement to molecular testing. This study was aimed to assess the clinical preference of DiaSorin LIAISON SARS-CoV-2 Ag chemiluminescence immunoassay.

methodsAn upper respiratory specimen was collected in a series of patients referred to the Laboratory Medicine service of Pederzoli Hospital (Peschiera del Garda, Verona, Italy) for screening or diagnosis of SARS-CoV-2 infection. Nasopharyngeal samples were assayed with DiaSorin LIAISON SARS-CoV-2 Ag test and Altona Diagnostics RealStar

resultsThe final study population consisted of 421 patients (median age, 48 years; 227 women), 301 (71.5%) with positive result of molecular testing, and 126 (29.9%) with cycle threshold (Ct) values of both

conclusionThe performance of this chemiluminescence immunoassay would not permit it to replace molecular testing for diagnosing SARS-CoV-2, but may enable rapid and efficient detection of subjects with high SARS-CoV-2 viral load, who are responsible for the largest proportion of infectious clusters.

Indexed as

antigenCOVID-19diagnosisimmunoassaySARS-CoV-2

Identifiers

PMID34421491
PMCPMC8343054
OpenAlexW3161590367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.